title: PHARMAC responds on TNF inhibitors for inflammatory arthritis.
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Peter
authors.initials: P
authors.lastname: Moodie
authors.forename: Rachel
authors.initials: R
authors.lastname: Grocott
authors.forename: Tommy
authors.initials: T
authors.lastname: Wilkinson
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000191:economics*; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D009313:National Health Programs / Q000191:economics*; D009520:New Zealand; D018579:Patient Selection; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha